← Back to Clinical Trials
Recruiting NCT07077824

NCT07077824 Effect of Stellate Ganglion Block on Arterial Catheterization Complications in Selected Group of Patients Undergoing Elective Cardiac Surgeries

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07077824
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Cardiac Surgery
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-07-15
Primary Completion 2026-01-16

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Stellate Ganglion Block Injection with Bupivicaine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-07-15 with a primary completion date of 2026-01-16.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Radial artery catheterization is the usual method for invasive monitoring in cardiac surgeries. Although it is relatively safe, complications do happen. Hematoma and ischemia are well known complications. Also, radial-to-femoral arterial pressure gradient (RFAPG) post bypass is a common event which affect management of a critical patient in a critical time. the study examines the effect of left stellate ganglion block (LSGB) on decreasing radial artery complications in cardiac surgeries

Eligibility Criteria

Inclusion Criteria: * • Multiple procedures with expected prolonged bypass time (\>100 min) * EF\< 35% * Moderate or severe Pulmonary hypertension Exclusion Criteria: * • Patient not willing to participate in the study. * History of strokes / Transient ischaemic attacks * History of Glaucoma. * History of allergy to local anaesthetic drugs. * Pre-existing contralateral phrenic nerve palsy. * Patients with existing coagulopathy. * BMI \>35

Contact & Investigator

Central Contact

abdallah M soudi

✉ Dr.soudi2014@med.asu.edu.eg

📞 +201111228925

Frequently Asked Questions

Who can join the NCT07077824 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07077824 currently recruiting?

Yes, NCT07077824 is actively recruiting participants. Contact the research team at Dr.soudi2014@med.asu.edu.eg for enrollment information.

Where is the NCT07077824 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07077824 clinical trial?

NCT07077824 is sponsored by Ain Shams University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology